Literature DB >> 22431722

PARPs and the DNA damage response.

Fabricio G Sousa1, Renata Matuo, Daniele G Soares, Alexandre E Escargueil, João A P Henriques, Annette K Larsen, Jenifer Saffi.   

Abstract

Adenosine diphosphate (ADP)-ribosylation is an important posttranslational modification catalyzed by a variety of enzymes, including poly (ADP ribose) polymerases (PARPs), which use nicotinamide adenine dinucleotide (NAD(+)) as a substrate to synthesize and transfer ADP-ribose units to acceptor proteins. The PARP family members possess a variety of structural domains, span a wide range of functions and localize to various cellular compartments. Among the molecular actions attributed to PARPs, their role in the DNA damage response (DDR) has been widely documented. In particular, PARPs 1-3 are involved in several cellular processes that respond to DNA lesions, which include DNA damage recognition, signaling and repair as well as local transcriptional blockage, chromatin remodeling and cell death induction. However, how these enzymes are able to participate in such numerous and diverse mechanisms in response to DNA damage is not fully understood. Herein, the DDR functions of PARPs 1-3 and the emerging roles of poly (ADP ribose) polymers in DNA damage are reviewed. The development of PARP inhibitors, their applications and mechanisms of action are also discussed in the context of the DDR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431722     DOI: 10.1093/carcin/bgs132

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  48 in total

Review 1.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  NELF-E is recruited to DNA double-strand break sites to promote transcriptional repression and repair.

Authors:  Samah W Awwad; Enas R Abu-Zhayia; Noga Guttmann-Raviv; Nabieh Ayoub
Journal:  EMBO Rep       Date:  2017-03-23       Impact factor: 8.807

3.  Perspective: Do Fasting, Caloric Restriction, and Diets Increase Sensitivity to Radiotherapy? A Literature Review.

Authors:  Philippe Icard; Luc Ollivier; Patricia Forgez; Joelle Otz; Marco Alifano; Ludovic Fournel; Mauro Loi; Juliette Thariat
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

Review 4.  Understanding nucleotide excision repair and its roles in cancer and ageing.

Authors:  Jurgen A Marteijn; Hannes Lans; Wim Vermeulen; Jan H J Hoeijmakers
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07       Impact factor: 94.444

Review 5.  Human RecQ helicases in DNA repair, recombination, and replication.

Authors:  Deborah L Croteau; Venkateswarlu Popuri; Patricia L Opresko; Vilhelm A Bohr
Journal:  Annu Rev Biochem       Date:  2014-03-03       Impact factor: 23.643

6.  The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Authors:  David Davidson; Yunzhe Wang; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2012-10-09       Impact factor: 3.850

7.  DNA damage tolerance: a double-edged sword guarding the genome.

Authors:  Gargi Ghosal; Junjie Chen
Journal:  Transl Cancer Res       Date:  2013       Impact factor: 1.241

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

Review 9.  Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Authors:  Qun Liu; Kristen M Turner; W K Alfred Yung; Kexin Chen; Wei Zhang
Journal:  Neuro Oncol       Date:  2014-05-07       Impact factor: 12.300

10.  Acetylation of Werner syndrome protein (WRN): relationships with DNA damage, DNA replication and DNA metabolic activities.

Authors:  Enerlyn Lozada; Jingjie Yi; Jianyuan Luo; David K Orren
Journal:  Biogerontology       Date:  2014-06-26       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.